rs11726117 — ALPK1 ALPK1 variant

Missense variant in the innate immune kinase ALPK1 (Met861Thr); the C allele is associated with elevated gout risk in East Asian populations through altered URAT1-mediated urate homeostasis and NF-κB inflammatory signaling

See your personal result for ALPK1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ALPK1 Met861Thr — Where Innate Immunity Meets Urate Clearance

Most people think of gout as a disease of diet — too much red meat, beer, or shellfish. That is partly true. But your kidneys' ability to excrete uric acid is equally determined by genetics, and one of the less obvious players is ALPK111 ALPK1
Alpha-kinase 1, a serine/threonine kinase that serves as a cytosolic innate immune sensor for bacterial metabolites and also regulates urate transport in the kidney. ALPK1 encodes a kinase best known as the master switch of the ALPK1-TIFA-NF-κB signaling axis22 ALPK1-TIFA-NF-κB signaling axis
A cellular alarm system: ALPK1 detects bacterial metabolites (ADP-heptose), phosphorylates the adaptor protein TIFA, which then activates the pro-inflammatory transcription factor NF-κB, triggering cytokine production, the innate immune pathway that detects gram-negative bacterial metabolites and triggers inflammatory cytokine production. But ALPK1 also turns out to regulate URAT133 URAT1
The urate transporter 1, encoded by SLC22A12 — the primary transporter responsible for reabsorbing uric acid from urine back into the bloodstream in renal proximal tubules. Inhibiting URAT1 is the mechanism of the gout drug probenecid, the kidney protein responsible for reabsorbing urate from the urine back into the bloodstream. The Met861Thr variant (rs11726117, T>C on the plus strand) sits in the kinase domain of ALPK1 and disrupts this regulatory balance.

The Mechanism

ALPK1 normally acts as a negative regulator of URAT1 expression: higher ALPK1 activity suppresses URAT1, which reduces urate reabsorption and keeps serum uric acid lower. The C allele (Met861Thr) at rs11726117 is associated with altered ALPK1 function and, in kidney cells exposed to monosodium urate crystals44 monosodium urate crystals
The needle-shaped crystals that form in joints and soft tissue when serum uric acid exceeds its solubility threshold (~6.8 mg/dL), triggering the acute inflammatory response of a gout attack, less effective suppression of URAT1 expression. The result is higher urate reabsorption, elevated serum uric acid, and increased susceptibility to both hyperuricemia and the inflammatory cascade that drives gout attacks.

The ALPK1 connection to inflammation matters beyond urate transport. ALPK1 phosphorylates TIFA55 TIFA
TRAF6-interacting protein with a forkhead-associated domain — a molecular bridge between ALPK1 sensing and NF-κB activation, which in turn activates TRAF6 and NF-κB, triggering a cascade of pro-inflammatory cytokines. Monosodium urate crystals may tap into this same pathway, potentially amplifying joint inflammation in individuals whose ALPK1 variant produces a more reactive signaling state.

The Evidence

Ko et al.66 Ko et al.
Ko AM et al. ALPK1 genetic regulation and risk in relation to gout. Int J Epidemiol, 2013 conducted a genome-wide association study of 1,351 Taiwanese aboriginal participants (511 gout cases, 840 controls) and found rs11726117 among the top hits, with the C allele carrying an odds ratio ≥1.44 (P ≤3.78×10⁻⁶). A replication in 511 Han Chinese participants confirmed the association, with OR ≥1.72 (P ≤4.08×10⁻³). The CC composite genotype with other ALPK1 variants showed OR = 1.83.

Kuo et al.77 Kuo et al.
Kuo TM et al. URAT1 inhibition by ALPK1 is associated with uric acid homeostasis. Rheumatology (Oxford), 2017 provided functional evidence in 492 Han Chinese participants and a transgenic mouse model. ALPK1 overexpression significantly lowered URAT1 protein levels (P=0.0045), and the T allele at rs11726117 was associated with reduced gout risk via the SLC22A12 pathway (OR 0.39 — meaning T carriers have roughly 61% lower odds of gout versus C/C homozygotes in this model). Monosodium urate crystal exposure inhibited URAT1 expression through ALPK1 upregulation, suggesting a feedback loop that is disrupted by the Met861Thr variant.

Tu et al.88 Tu et al.
Tu HP et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet, 2018 showed that combining ALPK1 CC with high-risk genotypes in ABCG2, SLC2A9, and SLC22A12 achieved a 99% positive predictive value for gout in Han Chinese (OR up to 55.0), underscoring the importance of ALPK1 in a polygenic gout risk model.

However, a Japanese replication study99 Japanese replication study
Chiba T et al. Common variant of ALPK1 is not associated with gout: a replication study. Hum Cell, 2015 in 903 gout cases and 1,302 controls found no significant association (minor allele frequency 0.26 vs 0.25, p=0.44), suggesting the effect may be population-specific or modified by linkage disequilibrium differences between ethnic groups. This limits the evidence level to moderate.

Practical Actions

For individuals with the risk genotype (CC or CT), the most actionable implication is heightened attention to urate management. The ALPK1-URAT1 pathway points toward renal urate handling as the primary mechanism — meaning dietary strategies that reduce the urate load reaching the kidneys and pharmacological URAT1 inhibitors (when clinically indicated) are the most directly relevant interventions.

Monitoring serum uric acid is the first step: knowing your baseline uric acid level tells you whether ALPK1 genotype is translating into biochemical risk. Target below 6 mg/dL to prevent crystal formation, below 5 mg/dL if you have had prior gout attacks.

Interactions

The strongest interactions documented in the literature are with the major urate transporter genes: rs2231142 in ABCG2 (the intestinal urate exporter), rs505802 in SLC22A12/URAT1 (renal urate reabsorption), and rs3825016 in SLC22A12. Tu et al. (2018) showed that stacking ALPK1 CC with CC homozygosity at ABCG2 rs2231142 and risk alleles at SLC2A9 and SLC22A12 raised the predictive value for gout to near certainty. These compound effects reflect how urate metabolism is governed by a network of transporters — ALPK1 appears to be a regulatory node that amplifies or dampens the net effect of this transporter ensemble.

Genotype Interpretations

What each possible genotype means for this variant.

TT Protective Genotype Normal

Two copies of the protective T allele — lowest ALPK1-related gout risk

The TT genotype preserves Met861 in the ALPK1 kinase domain, supporting the protein's ability to negatively regulate URAT1 expression in renal proximal tubules. When serum uric acid rises and monosodium urate crystals begin to form, ALPK1 upregulates in a feedback loop that suppresses further urate reabsorption — a protective mechanism that operates more efficiently in TT individuals.

This genotype does not eliminate gout risk entirely. Dietary purine load, fluid intake, other uric acid transporter variants (ABCG2, SLC2A9, SLC22A12), and metabolic factors (fructose consumption, insulin resistance) all independently contribute. ALPK1 TT simply means one favorable component in a polygenic system.

CT Intermediate Risk Intermediate

One protective and one risk allele — moderately elevated ALPK1-related gout risk

With one copy of the Met861Thr variant, your ALPK1 kinase domain is partially affected. The C allele introduces a threonine residue in place of methionine at position 861, a region within the catalytic domain of the kinase. This substitution alters the local protein structure in ways that reduce — but do not eliminate — the kinase's ability to downregulate URAT1.

Practically, this means your baseline serum uric acid may run slightly higher than TT individuals when other risk factors are also present. The effect size for a single C allele at rs11726117 is modest on its own; it becomes more clinically relevant when combined with high-risk variants in ABCG2, SLC2A9, or SLC22A12.

CC Elevated Risk High Risk

Two copies of the risk allele — highest ALPK1-related gout susceptibility

The CC genotype places threonine at position 861 in both copies of ALPK1's kinase domain. This missense change is predicted to alter the local structure of the catalytic domain, impairing the kinase's ability to downregulate URAT1 in response to rising uric acid. The net effect is a reduced braking mechanism on renal urate reabsorption.

In the Kuo et al. (2017) mouse model, ALPK1 overexpression caused a statistically significant drop in URAT1 protein levels (P=0.0045), and monosodium urate crystal exposure normally upregulates ALPK1 as a feedback response. In CC individuals, this upregulation is less effective — meaning the kidney is slower to reduce urate reabsorption when serum uric acid rises, allowing urate to accumulate and crystals to form more readily.

The association appears strongest in East Asian populations and was not replicated in a Japanese cohort (Chiba 2015), underscoring that additional genetic context (linkage disequilibrium, other urate transporter variants) modifies the phenotypic expression of this genotype. The evidence is therefore rated moderate rather than strong.